FL-MITSUBISHI-POWER
Renewable energy developer Ion Renewables, Ltd. (ION Renewables) has signed an exclusivity agreement with Mitsubishi Power Americas, Inc. (Mitsubishi Power) for four battery energy storage system (BESS) projects using Mitsubishi Power’s Emerald storage solutions totaling 185.5 megawatt (MW) / 371 megawatt-hours (MWh) in Ireland. These projects will provide Secure, Sustainable Electricity System (DS3) energy storage and system services including fast frequency and capacity response to Ireland’s National Grid, enabling the addition of more renewable energy. All four projects will be located at brownfield sites with existing electrical interconnects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622006036/en/
In addition to providing frequency response to the National Grid, the BESS projects will support three major energy initiative programs for Ireland and the European Union:
- Ireland’s Climate Action Plan to reach net-zero greenhouse gas emissions no later than 2050
- EirGrid Group’s DS3 program that addresses the challenges of integrating world-leading levels of renewable generation into the grid and targets having 70% of Ireland’s electricity come from renewables by 2030
- REPowerEU’s draft directive, which seeks to eliminate imported gas by 2030 and diversify energy sources
“We are delighted to be working with the Mitsubishi Power team to deliver these important projects,” said John Ward, Director, ION Renewables. “These installations represent a viable and economical solution to balance the network, strongly aligning with the principles of the REPowerEU draft directive. These projects demonstrate that effective solutions for storing energy can be achieved by utilizing renewable power that would otherwise be curtailed.”
Scheduled to come online in 2024, the four BESS projects will be Mitsubishi Power’s first in Europe, bringing the total global deployment of its Emerald storage solutions to more than 2 gigawatt-hours (GWh).
Mitsubishi Power’s Emerald storage solutions for Ion Renewables include project engineering, equipment supply, and a 10-year long-term service agreement.
According to Tom Cornell, Senior Vice President, Energy Storage Solutions, Mitsubishi Power Americas, these projects emphasize the importance of BESS adoption as a viable solution with more countries striving to meet their climate action goals. “Bringing our Emerald storage solutions to Ireland and working with Ion Renewables is an exciting moment for us. The continued adoption of battery storage technologies outside of the United States and the recognition of the important role they play in enabling renewable energy generation to reach net-zero cannot be overstated. Mitsubishi Power’s Emerald storage solutions will help Ireland reach its goal of 70% generation from renewable sources while ensuring the stability of the grid with a secure power system.”
Read more about some of Mitsubishi Power’s BESS projects:
- Innergex Orders Mitsubishi Power Emerald Storage Solution to Bring 425 Megawatt-hours of Battery Storage to Chile
- San Diego Gas & Electric Orders Mitsubishi Power Emerald Storage Solution to Add Capacity for High Energy Demand
- Mitsubishi Power and Powin Partner to Enhance California’s Grid Reliability with Two Battery Energy Storage Projects
- MHPS Will Supply Battery Energy Storage Systems to Help Balance the California Grid
- Key Capture Energy, Mitsubishi Hitachi Power Systems, and Powin Energy Partner to Add 200 MW of Battery Storage to the Texas Grid
About Mitsubishi Power Americas, Inc.
Mitsubishi Power Americas, Inc. (Mitsubishi Power) headquartered in Lake Mary, Florida, employs more than 2,300 power generation, energy storage, and digital solutions experts and professionals. Our employees are focused on empowering customers to affordably and reliably combat climate change while also advancing human prosperity throughout North, Central, and South America. Mitsubishi Power’s power generation solutions include gas, steam, and aero-derivative turbines; power trains and power islands; geothermal systems; PV solar project development; environmental controls; and services. Energy storage solutions include green hydrogen, battery energy storage systems, and services. Mitsubishi Power also offers intelligent solutions that use artificial intelligence to enable autonomous operation of power plants. Mitsubishi Power is a power solutions brand of Mitsubishi Heavy Industries, Ltd. (MHI). Headquartered in Tokyo, Japan, MHI is one of the world’s leading heavy machinery manufacturers with engineering and manufacturing businesses spanning energy, infrastructure, transport, aerospace, and defense. For more information, visit the Mitsubishi Power Americas website and follow us on LinkedIn .
About Ion Renewables, Ltd.
Ion Renewables, Ltd. (ION Renewables) was formed by top experts in the energy storage industry with the goal of deploying energy storage to provide grid balancing and renewables integration. We are developing and advising on projects in Ireland and worldwide through our network. In this current batch of projects in Ireland, ION Renewables is developing ESS facilities at large industrial load centres, providing rapid deployment and low environmental footprint on existing brownfield sites. These projects will assist in balancing the network by providing additional functionality to the grid to enable the further deployment of renewables and ultimately reduce Ireland's dependency on imported fossil fuels. For more information, visit the ION Renewables website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622006036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom